Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer

  • Authors:
    • Tatsuo Shimura
    • Masahiko Shibata
    • Kenji Gonda
    • Yuko Murakami
    • Masaru Noda
    • Kazunoshin Tachibana
    • Noriko Abe
    • Tohru Ohtake
  • View Affiliations

  • Published online on: March 21, 2019     https://doi.org/10.3892/ol.2019.10183
  • Pages: 5139-5146
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The prognostic impacts of preoperative C‑reactive protein (CRP) and interleukin (IL)‑6 expression levels in patients with breast cancer remain controversial. A total of 55 female patients with invasive breast cancer were enrolled, and preoperative prognostic parameters including IL‑6 and CRP were analyzed. Overall survival (OS) and recurrence‑free survival (RFS) were estimated using the Kaplan‑Meier method, and candidates' prognostic factors were examined using a Cox proportional hazard model. Using receiver operating characteristic curve analysis, IL‑6 at 10.0 pg/ml and CRP at 0.12 mg/dl were determined as threshold values to predict OS and RFS, respectively. Patients with IL‑6 ≥10.0 pg/ml had poorer OS compared with those with IL‑6 <10.0 pg/ml (P=0.003), and patients with CRP ≥0.12 mg/dl had poorer RFS compared with those with CRP <0.12 mg/dl (P<0.001). Serum IL‑6 level (hazard ratio, 13.230; 95% confidence interval, 1.285‑136.214; P=0.030) and triple‑negative subtype (hazard ratio, 11.739; 95% confidence interval, 1.415‑97.362; P=0.023) were independent prognostic factors for OS, and CRP expression level was an independent prognostic factor for RFS in patients with breast cancer (hazard ratio, 18.571; 95% confidence interval, 2.240‑153.949; P=0.007). In patients with invasive breast cancer, preoperative serum IL‑6 and triple‑negative subtype may be independent prognostic factors for OS, while for RFS, preoperative CRP may be a more accurate prognostic factor compared with those currently established.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Kwa M, Makris A and Esteva FJ: Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 14:595–610. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Albain KS, André F, Bergh J, et al Panel members, : Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Sanpaolo P, Barbieri V and Genovesi D: Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: A retrospective clinical study. Eur J Surg Oncol. 37:876–882. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A, et al: Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 27:4701–4708. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Tillett WS and Francis T: Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 52:561–571. 1930. View Article : Google Scholar : PubMed/NCBI

8 

Eklund CM: Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 48:111–136. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Fang Y, Xu C, Wu P, Zhang LH, Li DW, Sun JH, Li WF and Liao ZS: Prognostic role of C-reactive protein in patients with nasopharyngeal carcinoma: A meta-analysis and literature review. Medicine (Baltimore). 96:e84632017. View Article : Google Scholar : PubMed/NCBI

10 

Zheng Z, Zhou L, Gao S, Yang Z, Yao J and Zheng S: Prognostic role of C-reactive protein in hepatocellular carcinoma: A systematic review and meta-analysis. Int J Med Sci. 10:653–664. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Stevens L, Pathak S, Nunes QM, Pandanaboyana S, Macutkiewicz C, Smart N and Smith AM: Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: A systematic review. HPB (Oxford). 17:285–291. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Woo HD, Kim K and Kim J: Association between preoperative C-reactive protein level and colorectal cancer survival: A meta-analysis. Cancer Causes Control. 26:1661–1670. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Hu Q, Gou Y, Sun C, Ding W, Xu K, Gu B, Xia G and Ding Q: The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis. Urol Oncol. 32:50.e1–50.e8. 2014. View Article : Google Scholar

14 

Luo Y, Fu SJ, She DL, Xiong HU and Yang LI: Preoperative C-reactive protein as a prognostic predictor for upper tract urothelial carcinoma: A systematic review and meta-analysis. Mol Clin Oncol. 3:924–928. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ and Xu Q: Prognostic role of C-reactive protein in prostate cancer: A systematic review and meta-analysis. Asian J Androl. 16:467–471. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Allin KH, Nordestgaard BG, Flyger H and Bojesen SE: Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: A cohort study. Breast Cancer Res. 13:R552011. View Article : Google Scholar : PubMed/NCBI

17 

Sicking I, Edlund K, Wesbuer E, Weyer V, Battista MJ, Lebrecht A, Solbach C, Grinberg M, Lotz J, Hoffmann G, et al: Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS One. 9:e1113062014. View Article : Google Scholar : PubMed/NCBI

18 

Frydenberg H, Thune I, Lofterød T, Mortensen ES, Eggen AE, Risberg T, Wist EA, Flote VG, Furberg AS, Wilsgaard T, et al: Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat. 155:345–354. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, McArdle CS and McMillan DC: Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer. 96:891–895. 2007. View Article : Google Scholar : PubMed/NCBI

20 

Tibau A, Ennis M and Goodwin PJ: Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. Breast Cancer Res Treat. 141:485–493. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P and Dirix LY; Salgado R1, : Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P and Dirix LY: Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 103:642–646. 2003. View Article : Google Scholar : PubMed/NCBI

22 

Knüpfer H and Preiss R: Significance of interleukin-6 (IL-6) in breast cancer (Review). Breast Cancer Res Treat. 102:129–135. 2007. View Article : Google Scholar : PubMed/NCBI

23 

Dethlefsen C, Højfeldt G and Hojman P: The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 138:657–664. 2013. View Article : Google Scholar : PubMed/NCBI

24 

Al-Youzbaki WB, Al-Youzbaki NB and Telfah MM: Tissue polypeptide antigen & interleukin-6: Are their serum levels a predictor for response to chemotherapy in breast cancer? Pak J Med Sci. 30:1108–1112. 2014. View Article : Google Scholar : PubMed/NCBI

25 

Ravishankaran P and Karunanithi R: Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol. 9:182011. View Article : Google Scholar : PubMed/NCBI

26 

Babaei Z, Moslemi D, Parsian H, Khafri S, Pouramir M and Mosapour A: Relationship of obesity with serum concentrations of leptin, CRP and IL-6 in breast cancer survivors. J Egypt Natl Canc Inst. 27:223–229. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Honjo Y, Nangia-Makker P, Inohara H and Raz A: Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res. 7:661–668. 2001.PubMed/NCBI

28 

Song YK, Billiar TR and Lee YJ: Role of galectin-3 in breast cancer metastasis: Involvement of nitric oxide. Am J Pathol. 160:1069–1075. 2002. View Article : Google Scholar : PubMed/NCBI

29 

Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V and Raz A: Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer. 127:2530–2541. 2010. View Article : Google Scholar : PubMed/NCBI

30 

Chen C, Duckworth CA, Zhao Q, Pritchard DM, Rhodes JM and Yu LG: Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res. 19:1693–1704. 2013. View Article : Google Scholar : PubMed/NCBI

31 

Van Eckyen E: Breast tumours. TNM classification of malignant tumours. 8th. Brieley JD, Gospodarowicz MK and Wittekind C: John Wiley and Sons, Ltd.; West Sussex: pp. 151–158. 2017

32 

Faggioli L, Costanzo C, Merola M, Bianchini E, Furia A, Carsana A and Palmieri M: Nuclear factor kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line. Eur J Biochem. 239:624–631. 1996. View Article : Google Scholar : PubMed/NCBI

33 

Robinson EK, Sneige N and Grimm EA: Correlation of interleukin 6 with interleukin 1alpha in human mammary tumours, but not with oestrogen receptor expression. Cytokine. 10:970–976. 1998. View Article : Google Scholar : PubMed/NCBI

34 

Fontanini G, Campani D, Roncella M, Cecchetti D, Calvo S, Toniolo A and Basolo F: Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. Br J Cancer. 80:579–584. 1999. View Article : Google Scholar : PubMed/NCBI

35 

Toi M, Inada K, Suzuki H and Tominaga T: Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat. 36:193–204. 1995. View Article : Google Scholar : PubMed/NCBI

36 

Heer K, Kumar H, Read JR, Fox JN, Monson JR and Kerin MJ: Serum vascular endothelial growth factor in breast cancer: Its relation with cancer type and estrogen receptor status. Clin Cancer Res. 7:3491–3494. 2001.PubMed/NCBI

37 

Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S and Bundred NJ: Serum vascular endothelial growth factor in breast cancer. Anticancer Res 27 (5B). 3481–3487. 2007.

38 

Hodorowicz-Zaniewska D, Kibil W, Małek A, Szpor J, Kulig J and Sztefko K: Evaluation of serum concentrations of vascular endothelial growth factor (VEGF) in breast cancer patients. Pol J Pathol. 63:255–260. 2012. View Article : Google Scholar : PubMed/NCBI

39 

Greenberg S and Rugo HS: Triple-negative breast cancer: Role of antiangiogenic agents. Cancer J. 16:33–38. 2010. View Article : Google Scholar : PubMed/NCBI

40 

Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI

41 

Dossus L, Jimenez-Corona A, Romieu I, Boutron-Ruault MC, Boutten A, Dupré T, Fagherazzi G, Clavel-Chapelon F and Mesrine S: C-reactive protein and postmenopausal breast cancer risk: Results from the E3N cohort study. Cancer Causes Control. 25:533–539. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Shimura, T., Shibata, M., Gonda, K., Murakami, Y., Noda, M., Tachibana, K. ... Ohtake, T. (2019). Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer. Oncology Letters, 17, 5139-5146. https://doi.org/10.3892/ol.2019.10183
MLA
Shimura, T., Shibata, M., Gonda, K., Murakami, Y., Noda, M., Tachibana, K., Abe, N., Ohtake, T."Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer". Oncology Letters 17.6 (2019): 5139-5146.
Chicago
Shimura, T., Shibata, M., Gonda, K., Murakami, Y., Noda, M., Tachibana, K., Abe, N., Ohtake, T."Prognostic impact of interleukin‑6 and C‑reactive protein on patients with breast cancer". Oncology Letters 17, no. 6 (2019): 5139-5146. https://doi.org/10.3892/ol.2019.10183